Cargando…

Gender, hormone therapy, and HIV: what should cardiologists know?

Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critic...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, C. A., Rikhi, R. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470229/
https://www.ncbi.nlm.nih.gov/pubmed/30671882
http://dx.doi.org/10.1007/s12471-019-1233-6
_version_ 1783411754749919232
author Martinez, C. A.
Rikhi, R. R.
author_facet Martinez, C. A.
Rikhi, R. R.
author_sort Martinez, C. A.
collection PubMed
description Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements.
format Online
Article
Text
id pubmed-6470229
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bohn Stafleu van Loghum
record_format MEDLINE/PubMed
spelling pubmed-64702292019-05-03 Gender, hormone therapy, and HIV: what should cardiologists know? Martinez, C. A. Rikhi, R. R. Neth Heart J Point of View Transgender individuals represent the fastest growing minority in the United States and are disproportionately affected by HIV. Hormone therapy is the most common treatment for gender dysphoria in transgender individuals. As HIV is an independent risk factor for coronary artery disease, it is critical to further research the influence masculinising and feminising hormone therapies have on cardiovascular disease. There is a clinical need for evidence-based guidelines for cardiologists to follow to effectively care for and treat transgender patients. For this to be done, the interplay between HIV, hormone therapy, and cardiovascular disease must be better understood through collaboration between researchers and clinicians to achieve maximum benefit from recent advancements. Bohn Stafleu van Loghum 2019-01-22 2019-05 /pmc/articles/PMC6470229/ /pubmed/30671882 http://dx.doi.org/10.1007/s12471-019-1233-6 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Point of View
Martinez, C. A.
Rikhi, R. R.
Gender, hormone therapy, and HIV: what should cardiologists know?
title Gender, hormone therapy, and HIV: what should cardiologists know?
title_full Gender, hormone therapy, and HIV: what should cardiologists know?
title_fullStr Gender, hormone therapy, and HIV: what should cardiologists know?
title_full_unstemmed Gender, hormone therapy, and HIV: what should cardiologists know?
title_short Gender, hormone therapy, and HIV: what should cardiologists know?
title_sort gender, hormone therapy, and hiv: what should cardiologists know?
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470229/
https://www.ncbi.nlm.nih.gov/pubmed/30671882
http://dx.doi.org/10.1007/s12471-019-1233-6
work_keys_str_mv AT martinezca genderhormonetherapyandhivwhatshouldcardiologistsknow
AT rikhirr genderhormonetherapyandhivwhatshouldcardiologistsknow